SILVER SPRING, Md., April 16, 2012 /PRNewswire/ -- Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" or "Sunpeaks Ventures") and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS") are pleased to announce that HDS will be an official exhibitor at the Thrombosis and Hemostasis Summit of North America (the "THSNA") to be held May 3-5, 2012 at the Hyatt Regency Chicago.
"Participation as an official exhibitor at this year's THSNA will provide us with the opportunity to showcase the benefits of Clotamin® and interact with over 1,500 clinicians and allied health care professionals on the front line of care for patients with bleeding and/or clotting disorders," stated Mackie A. Barch, CEO of Sunpeaks Ventures. "We look forward to meeting face to face with the many physicians, nurses, pharmacists, and laboratory professionals that are expected to attend the summit from across North America."
The Thrombosis and Hemostasis Summit of North America is a comprehensive scientific meeting dedicated to thrombosis and hemostasis issues. This first-ever joint summit is a collaboration of the leading non-profit organizations in both fields, including the American Thrombosis & Hemostasis Network, the Anticoagulation Forum, the Hemostasis & Thrombosis Research Society, the North American Specialized Coagulation Laboratory Association, the National Blood Clot Alliance, and The Thrombosis Interest Group of Canada.
Clotamin® is the world's first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® or other anticoagulants (blood thinners).
About Sunpeaks Ventures, Inc.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is a nationally focused, value-added distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
For additional information, please visit www.sunpeaksventures.com.
Contact: Financial Insights 888-248-8491 or [email protected]
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures' actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures' filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Sunpeaks Ventures, Inc.